Virginia Li digs into more promising data for NK CAR cell therapy, this time from Nkarta who share price doubled on the announcement. We listen to an extract from this week’s KOL View Live discussion between Michael Flanagan and Xianxin Hua, professor of cancer biology at the University of Pennsylvania’s Perelman School of Medicine, about the progress of CAR-T therapies as potential treatments for solid tumours. And Simon King provides some early thoughts on key trends from first quarter earnings season, including uncertainty around future COVID-19-related revenues and Big Pharma’s appetite for M&A.

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör FirstWord Pharma. Innehållet i podden är skapat av FirstWord Pharma och inte av, eller tillsammans med, Poddtoppen.